Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include FDA approval of baxdrostat (Baxfendy) as the first-in-class aldosterone synthase inhibitor for adults with uncontrolled hypertension, phase 3 TETON-1 data showing inhaled treprostinil preserved lung function in idiopathic pulmonary fibrosis, a discussion with Klaus Rabe, MD, PhD, on the mixed AERIFY results for itepekimab and what they mean for the drug's COPD approval pathway, FDA accelerated approval of bulevirtide-gmod (Hepcludex) as the first treatment for chronic hepatitis delta virus infection, and topline phase 3 TRIUMPH-1 results showing retatrutide achieved up to 28.3% body weight reduction at 80 weeks in adults with obesity.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of May 17, 2026 — let's jump in!

FDA Approves Baxdrostat for Uncontrolled Hypertension on Background Therapy

The FDA approved baxdrostat (Baxfendy; AstraZeneca) on May 18 as the first aldosterone synthase inhibitor for adults with hypertension not adequately controlled on 2 or more antihypertensive agents, introducing a first-in-class mechanism targeting aldosterone production upstream of mineralocorticoid receptor blockade. In the phase 3 BaxHTN trial, baxdrostat 2 mg produced a placebo-adjusted seated systolic blood pressure reduction of 9.8 mmHg at week 12 (

 <.001), with consistent effects across uncontrolled and resistant hypertension subgroups; key safety considerations include hyperkalemia, reported in up to 10.2% of patients at the 2 mg dose, and hyponatremia.

TETON-1: Treprostinil Preserved Lung Function in Idiopathic Pulmonary Fibrosis

Phase 3 TETON-1 results presented at ATS 2026 and simultaneously published in the 

 showed that nebulized treprostinil (Tyvaso) met its primary endpoint, demonstrating superiority over placebo in preserving absolute FVC by 130.1 mL over 52 weeks in patients with IPF, with pooled TETON-1 and TETON-2 analyses showing a 31% reduction in clinical worsening risk and a 48% reduction in acute IPF exacerbations. United Therapeutics plans to file a supplemental NDA with a priority review request by the end of summer 2026; the therapy remains investigational for IPF, though both the FDA and European Medicines Agency have granted it orphan designation for this indication.

Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus Rabe, MD, PhD

 at ATS 2026, Klaus Rabe, MD, PhD, addressed the discordant AERIFY results for itepekimab — an anti–IL-33 monoclonal antibody that reduced moderate or severe COPD exacerbations by 27.1% in AERIFY-1 but failed to replicate the finding in AERIFY-2 despite nearly identical trial designs — explaining that positive results from a single trial are unlikely to support regulatory submission, and that additional clinical evidence will be needed before a regulatory pathway becomes viable. Rabe also cautioned against overinterpreting divergent FEV₁ signals across the 2 trials, noting inconsistent dose-response patterns, and characterized itepekimab as unlikely to become clinically available in the near term.

Bulevirtide Receives Historic First FDA Approval for Chronic Hepatitis Delta

The FDA granted accelerated approval on May 22 to bulevirtide-gmod (Hepcludex; Gilead Sciences), the first approved therapy for chronic hepatitis delta virus (HDV) infection in the US, indicated for adults without cirrhosis or with compensated cirrhosis based on phase 3 MYR301 data demonstrating reductions in HDV RNA and ALT normalization through up to 144 weeks of treatment. The first-in-class entry inhibitor — which blocks HDV and HBV entry into liver cells — received Breakthrough Therapy, Orphan Drug, and Priority Review designations; the label carries a boxed warning for severe acute exacerbations of HDV and HBV upon discontinuation.

Retatrutide Meets Weight Loss Endpoints in Phase 3 Obesity Trial

Topline results from the phase 3 TRIUMPH-1 trial announced May 21 showed that all 3 doses of retatrutide — a first-in-class GIP/GLP-1/glucagon triple receptor agonist — met the primary and key secondary weight reduction endpoints at 80 weeks in 2,339 adults with obesity or overweight and at least 1 weight-related comorbidity, with the 12 mg dose achieving 28.3% mean body weight loss versus 3.9% on placebo and 62.5% of patients reaching ≥25% weight loss. Seven additional TRIUMPH program readouts are expected in 2026, including TRIUMPH-2 in obesity with type 2 diabetes and TRIUMPH-3 in obesity with established cardiovascular disease; retatrutide remains investigational and available only to clinical trial participants.

Articles

FDA cleared baxdrostat as the first aldosterone synthase inhibitor for uncontrolled hypertension, delivering clinically meaningful SBP lowering with hyperkalemia as a notable risk. In IPF, nebulized treprostinil preserved FVC over 52 weeks and reduced clinical worsening and acute exacerbations, supporting a planned supplemental NDA. Discordant AERIFY outcomes weaken the near-term COPD regulatory outlook for itepekimab, with inconsistent efficacy signals across near-identical trials. Accelerated approval of bulevirtide establishes the first US therapy for chronic HDV, while retatrutide posted substantial 80‑week weight loss in phase 3 obesity.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Pulmonary Fibrosis

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

The HCPFive: Top News for Healthcare Providers from the Week of 05/17

Mark G. Lebwohl, MD, the dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai,

Phase 3b Data on Ixekizumab, Tirzepatide for Psoriasis and Overweight, With Mark Lebwohl, MD

 suggest combining ixekizumab (Taltz) with tirzepatide (Zepbound) may significantly improve outcomes for patients with moderate-to-severe plaque psoriasis and obesity or overweight, according to Mark Lebwohl, MD, of the Icahn School of Medicine at Mount Sinai.

The 52-week, randomized phase 3b TOGETHER-PsO trial evaluated ixekizumab alone versus ixekizumab combined with tirzepatide in 274 adults with psoriasis and obesity or overweight. By Week 36, investigators found 27.1% of patients receiving combination therapy achieved both complete skin clearance, defined as Psoriasis Area and Severity Index (PASI) 100, and at least 10% weight loss, compared with 5.8% of patients treated with ixekizumab alone (

 < .001). Investigators also observed a 40% relative increase in PASI 100 responses with the combination regimen.

, Lebwohl said the findings reinforce growing recognition that psoriasis and obesity should not be managed separately, given their overlapping inflammatory pathways.

“We know that [for] obesity, the fat cells of obesity secrete cytokines that make psoriasis worse,” Lebwohl explained, noting patients with obesity often respond less effectively to biologic medications by themselves. According to Lebwohl, adding weight management therapy can improve biologic efficacy while simultaneously addressing broader health risks associated with obesity.

Lebwohl suggested the study may also influence dermatology practice patterns, predicting dermatologists will become increasingly comfortable prescribing anti-obesity medications directly for patients with inflammatory skin disease. He described monitoring requirements for incretin-based therapies as relatively straightforward and emphasized their potential benefits beyond weight reduction, including improvements in blood pressure, cholesterol, diabetes risk, and overall quality of life.

Lebwohl also pointed to related findings from the TOGETHER-PsA trial in psoriatic arthritis, where combination treatment similarly demonstrated stronger outcomes than biologic therapy alone. He noted weight loss interventions have increasingly become a core strategy when biologic treatments appear less effective in patients with obesity.

Overall, Lebwohl described the combination approach in his interview as a potentially important advancement in comprehensive psoriasis care, particularly for patients with obesity or overweight whose inflammatory disease may be amplified by metabolic dysfunction.

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight. Eli Lilly. February 18, 2026. Accessed May 24, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together-0

Armstrong et al. Addressing the Obesity-Psoriasis Connection: Prevalence, Incidence, and Comorbidity Insights from a Large US Population of 19.9 Million (2018-2024). Presented at Maui Derm, 2026. Accessed May 24, 2026.

Videos

This interview highlights recent phase 3b data from the TOGETHER-PsO trial on ixekizumab and tirzepatide for psoriasis and obesity or overweight.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Michael Miedema, MD, is the director of cardiovascular prevention at the Allina Health Minneapolis Heart Institute.

Addressing the Manifold Barriers in Hypertension, With Michael Miedema, MD

Despite the prevalence of antihypertensive therapies and widespread awareness campaigns, half of the US population has hypertension. Among these patients, roughly 4 out of 5 adults in the US with 

 have blood pressure well above the guideline-recommended goal of <130/80 mmHg. In 2023, hypertension was noted as the primary cause or a contributing factor in nearly 664,000 deaths in the US.

There has been a longstanding debate regarding the best path forward to solve this ongoing crisis, particularly in an era of rapid advancement in both treatments and technologies available. Recent research has uncovered that only 2 in 3 US adults suffering from hypertension actually receive medical treatment.

“It’s a multifactorial issue. Multiple readings are needed at multiple different times in multiple different settings to come up with a formal diagnosis, and that takes time, money, and effort,” Michael Miedema, MD, director of cardiovascular prevention at the Allina Health Minneapolis Heart Institute, told 

 in an exclusive interview. “I think our treatment agents could also be a little bit better – we have better evidence that using a low dose combination of several agents is more effective than a high dose of 1 agent, but most of our patients don’t want to take multiple pills.”

Miedema points out 3 major components that need to be overhauled before hypertension control can have a meaningful effect. These include diagnosis, treatment, and monitoring, widely considered the 3 main components of management.

The diagnostic process for hypertension typically involves multiple measurements to account for subtle influences on blood pressure. The current American Heart Association (AHA) and American College of Cardiology (ACC) hypertension guidelines recommend that clinicians generate a measure of in-office blood pressure by taking an average of several individual measurements taken at different times.

In addition to its inconvenience for patients, this strategy overlooks such issues as “white-coat hypertension,” a situation in which patients will present with higher blood pressure in clinic due to stress related to the environment. To this end, experts have recommended having patients with suspected hypertension take multiple measurements outside of the clinic as well, reporting the values to their healthcare provider to bolster the potential diagnosis.

Treating hypertension typically involves a combination of medical therapy and lifestyle interventions. Treatment regimens generally include multiple medications taken at once, such as ACE, ARNIs, and beta-blockers. These drugs are far more effective at lowering blood pressure in tandem than individually, leading clinicians to prescribe patients multiple drugs at once. This significantly increases pill burden for patients and can negatively impact adherence.

Finally, the blood pressure monitoring process is significantly handicapped by patient adherence. Current guidelines recommend regular monitoring at home via similar cuffs to those used in the clinic. However, these devices are typically bulky and inefficient, requiring patients to refrain from talking, using their phones, or otherwise engaging in any activity that could offset the measurements taken.

Ultimately, Miedema acknowledges the shortcomings of modern hypertension treatment and monitoring, while encouraging further research into both the pharmacological and technological approaches to disease management.

“The current monitoring methods we have are not optimal. A 24-hour blood pressure monitor works well, and the data are very supportive, but they’re pretty annoying for patients,” Miedema said. “This is the one area where I think we have the most promise moving forward – the technology is getting better. I think we’ll have better methods to assess blood pressure in the near future.”

Editors’ Note: Miedema reports no relevant disclosures.

Hardy ST, Jaeger BC, Emanuel E, Muntner P. Blood Pressure Above Goal Among US Adults With Hypertension. JAMA. Published online February 02, 2026. 

Wadhera R, Dhruva S, Bikdeli B. et al. Cardiovascular Statistics in the United States, 2026: JACC Stats. 

https://doi.org/10.1016/j.jacc.2025.12.027

Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82(10). 

Miedema highlights the shortcomings of current technology and medication for what is among the US’s fastest-growing and most devastating conditions.

Jeffrey Thiboutot, MD, from Johns Hopkins University.

Cryobiopsy Outperforms Forceps in Transbronchial Lung Biopsy in RCT

A 1.1-mm cryoprobe used for transbronchial lung biopsy significantly outperformed standard 2.0-mm forceps on diagnostic yield, specimen size, and histologic quality in the first randomized controlled trial to directly compare the 2 approaches.

Jeffrey Thiboutot, MD, MHS, assistant professor of medicine and interventional pulmonologist at Johns Hopkins University School of Medicine in Baltimore, Maryland, was the study's lead investigator and presented its findings at the 

2026 American Thoracic Society (ATS) International Conference

The prospective, multicenter randomized controlled trial (RCT) enrolled 490 participants across 9 sites, randomized 1:1 to transbronchial biopsy using either a 1.1-mm cryoprobe (n = 245) or 2.0-mm forceps (n = 245) for 3 indications: pulmonary parenchymal lesions (PPL; n = 192), lung transplant allograft evaluation (n = 249), and diffuse parenchymal lung disease (n = 49). The primary endpoint was overall diagnostic yield assessed by an independent, blinded central pathology core using ATS/ACCP strict criteria for PPL, ISHLT classifiable definitions of acute cellular rejection for lung transplant, and specific histopathologic patterns for diffuse parenchymal lung disease. The composite safety endpoint was bleeding grade ≥3 CTCAE, pneumothorax requiring chest drainage, or respiratory failure within 30 days, overseen by an independent Data Safety and Monitoring Board.

Overall diagnostic yield was significantly higher in the cryoprobe arm than the forceps arm (89% vs 79%; 

 = .003). Indication-specific analyses showed statistically significant superiority for PPL (83% vs 70%; 

 = .04) and lung transplant allograft evaluation (96% vs 89%; 

 = .03). The diffuse parenchymal lung disease subgroup did not reach statistical significance (72% vs 63%; 

 = .55), a result Thiboutot attributed to underpowering — with only 49 patients in that arm compared with approximately 200 to 250 in the other 2, the absolute difference in diagnostic yield was comparable across all three indications. Specimen quality metrics uniformly favored the cryoprobe: mean specimen area was 24.2 mm² with the cryoprobe versus 13.1 mm² with forceps (

 <.001), the Histologic Accessibility Score was 5.6 versus 5.2 (

 <.001), and crush artifact was markedly lower at 2.7% versus 8.9% (

 <.001). Crush artifact — mechanical distortion of tissue during forceps retrieval — is a recognized source of uninterpretable pathology specimens and a major contributor to the estimated 30% miss rate of conventional transbronchial biopsy.

Regarding safety, no events meeting the composite endpoint occurred in the cryoprobe arm. Four events were recorded in the forceps arm — all pneumothoraces requiring chest drainage — yielding a complication rate of approximately 1.6%, consistent with published forceps biopsy literature. The cryoprobe arm was not powered to demonstrate a statistically significant safety difference, but the absence of any events in that arm was nonetheless notable.

"Cryobiopsy is safe, and it's nothing you need to be worried about — this is not the same procedure that most people think of when they think of cryobiopsy. The traditional cryobiopsies were with much larger probes where you had to remove the entire scope out of the airway. This is a simple procedure done in the same exact method as standard forceps,” he said.

Thiboutot predicted adoption will proceed first through the interventional pulmonology and lung transplant communities before expanding to general pulmonology training programs, with barriers including fellow training curricula, per-use probe cost relative to forceps, and the upfront device investment — topics his group plans to address through a forthcoming cost-efficacy analysis.

Thiboutot’s disclosures include Erbe USA and Verathon.

Thiboutot J, et al. A randomized controlled trial of cryobiopsy versus forceps for transbronchial lung biopsy. Presented at: American Thoracic Society International Conference; San Francisco, California; May 2026. [Abstract pending publication]

Jeffrey Thiboutot, MD, discussed efficacy advantages seen in the trial at ATS 2026.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

 has approved bulevirtide (Hepcludex) injection for chronic 

 in adults without cirrhosis or with compensated cirrhosis.¹ Bulevirtide is the first FDA-approved therapy for chronic HDV infection. The agency granted approval of the first-in-class entry inhibitor to Gilead Sciences on May 22, 2026, under the Accelerated Approval pathway.¹

Until this decision, no antiviral was approved in the US specifically for HDV, and clinicians relied on off-label, interferon-based regimens with limited efficacy.

"Today's approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available," said Wendy Carter, DO, acting director of the Office of Infectious Diseases in FDA’s Center for Drug Evaluation and Research. "For individuals living with this chronic viral infection, this new treatment option offers hope in managing a disease that can rapidly progress to serious liver complications."

MYR301, Buleviritde, and Hepatitis D Efficacy

The approval was supported by MYR301, a multicenter, randomized, open-label, parallel-arm phase 3 trial. Participants were assigned to immediate treatment with bulevirtide 8.5 mg once daily for 144 weeks or to delayed treatment, consisting of a 48-week observational period followed by bulevirtide 8.5 mg once daily for 96 weeks.¹

The primary efficacy endpoint was combined response at week 48. Combined response was defined as undetectable HDV RNA, reported as below the lower limit of quantification (LLOQ) of 50 IU/mL with target not detected, or a decline of at least 2 log10 IU/mL from baseline, together with alanine aminotransferase (ALT) normalization.¹

At week 48, combined response was achieved in 48% of patients in the bulevirtide group compared with 2% in the delayed-treatment group.¹ The 46-percentage-point difference formed the basis for the accelerated approval, with combined response serving as the primary efficacy endpoint. In MYR301, virologic suppression continued to deepen through 144 weeks, supporting extended dosing in responding patients.¹

Bulevirtide safety profile and boxed warning

Among secondary measures, the rate of undetectable HDV RNA at week 48 was 20% in the bulevirtide group compared with 0% in the delayed-treatment group.¹ Virologic suppression deepened with continued dosing. The proportion of patients with undetectable HDV RNA rose to 36% at week 96 and to 50% at week 144, indicating progressive response across the 144-week treatment period.¹

The most common adverse reactions reported with the once-daily injection include headache, abdominal pain, fatigue, and pruritus, along with injection site reactions.¹ Hypersensitivity reactions, including anaphylaxis, have also been reported.

The label carries a boxed warning for severe acute exacerbations of hepatitis. Discontinuation of bulevirtide may result in severe acute exacerbations of HDV and HBV infection, according to the FDA.¹ The warning is clinically relevant given the agent's chronic, multiyear dosing schedule.

The FDA granted bulevirtide Breakthrough Therapy and Orphan Drug designations, and the application received priority review.¹ The agency described the decision as part of its effort to expedite access to therapies for diseases with limited or no treatment options.¹

Bulevirtide already holds full marketing authorization in the European Union, the United Kingdom, and Switzerland for chronic HDV.

US Food and Drug Administration. FDA approves first treatment for chronic hepatitis delta virus (HDV) infection. Published May 22, 2026. Accessed May 22, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-hepatitis-…

Wedemeyer H, Aleman S, Brunetto MR, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. 

. 2023;389(1):22-32. doi:10.1056/NEJMoa2213429

The FDA granted accelerated approval to bulevirtide, a first-in-class entry inhibitor, for adults with chronic HDV infection without cirrhosis or with compensated cirrhosis, marking the first US-approved HDV therapy. Approval was supported by the phase 3 MYR301 trial using a week-48 combined endpoint of HDV RNA reduction/undetectability plus ALT normalization, achieved in 48% versus 2% with delayed treatment. Virologic responses deepened through 144 weeks. Key safety considerations include common injection-related AEs, rare hypersensitivity, and a boxed warning for severe hepatitis exacerbations after discontinuation.

Until this decision, clinicians relied on off-label, interferon-based regimens with limited efficacy.

FDA News

Hepatology

Ashkan Shoamanesh, MD, is an associate professor of medicine and the Marta and Owen Boris Chair in Stroke Research and Care at McMaster University.

Ashkan Shoamanesh, MD, discusses a series of abstracts presented at ESOC 2026 reinforcing asundexian’s protective effect in patients at risk of ischemic stroke or TIA.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Secondary Analyses of OCEANIC-STROKE Confirm Efficacy of Asundexian

Kilian Eyerich, MD, PhD, is chair and professor at the Department of Dermatology and Venerology of the University of Freiburg, Germany, as well as a guest professor at the Karolinska Institute in Stockholm, Sweden.

This segment of a Q&A interview with Kilian Eyerich, MD, PhD, highlights the signficance of the LumiNE phase 3 study on lebrikizumab.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Significance of New Phase 3 Lebrikizumab Trial in Nummular Eczema, With Kilian Eyerich, MD, PhD

Explore where ezetimibe and bempedoic acid fit for statin‑reluctant patients, lowering LDL with proven outcomes and diabetes benefits.

Advancing ASCVD Management with PCSK9 Inhibitors

The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction

Geoffrey Tison, MD, MPH, is the co-director of the University of California San Francisco Center for Biosignal Research.

Joshua Barrios, PhD, and Geoffrey Tison, MD, MSc, discuss their new AI echo’s comparative superiority in identifying cardiovascular disease.

New AI Model Outperforms Standard Echocardiograms in Heart Disease Detection

A new phase 3 study is evaluating lebrikizumab in at least 270 patients with nummular eczema over 48 weeks.


Phase 3 LumiNE Trial to Assess Lebrikizumab in Nummular Eczema, With Kilian Eyerich, MD, PhD

Jane Wilcox, MD, MSc, is the section chief of heart failure treatment and recovery at Northwestern Feinberg School of Medicine.

Wilcox discusses the recent HFSA statement aiming to identify the unique characteristics of HFmrEF and define an alternative treatment pathway.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

HFmrEF as a Unique Phenotype of Heart Failure, With Jane Wilcox, MD, MSc

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The FDA accepted Bayer’s sNDA for finerenone in adults with type 1 diabetes and CKD based on albuminuria data from FINE-ONE.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

FDA Grants Priority Review to Finerenone for Type 1 Diabetes and CKD

Retatrutide successfully reduced body weight versus placebo in adults with obesity or overweight in topline phase 3 TRIUMPH-1 results.

Klaus F. Rabe, MD, PhD, from LungenClinic Grosshansdorf GmbH. 

Klaus Friedrich Rabe, MD, PhD, spoke at ATS about the mixed phase 3 AERIFY trial findings on itepekimab, an anti–IL-33 monoclonal antibody, in COPD.

Latest News

The HCPFive: Top News for Healthcare Providers from the Week of 05/17

Phase 3b Data on Ixekizumab, Tirzepatide for Psoriasis and Overweight, With Mark Lebwohl, MD

Addressing the Manifold Barriers in Hypertension, With Michael Miedema, MD

Cryobiopsy Outperforms Forceps in Transbronchial Lung Biopsy in RCT

Bulevirtide Receives Historic First FDA Approval for Chronic Hepatitis Delta